NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $13.99 -0.25 (-1.76%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$14.25 +0.26 (+1.85%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Crescent Biopharma Stock (NASDAQ:CBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$13.66▼$14.4650-Day Range$13.99▼$20.8852-Week Range$8.72▼$27.41Volume228,686 shsAverage Volume531,328 shsMarket Capitalization$519.59 millionP/E RatioN/ADividend YieldN/APrice Target$29.60Consensus RatingModerate Buy Company Overview Crescent Biopharma, Inc. (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates. Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources. The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships. Additional reliable public information about its history, geographic operations and executive leadership is limited.AI Generated. May Contain Errors. Read More Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 320th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCrescent Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCrescent Biopharma has a consensus price target of $29.60, representing about 111.6% upside from its current price of $13.99.Amount of Analyst CoverageCrescent Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Crescent Biopharma are expected to decrease in the coming year, from ($2.93) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Crescent Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.20% of the float of Crescent Biopharma has been sold short.Short Interest Ratio / Days to CoverCrescent Biopharma has a short interest ratio ("days to cover") of 8.51.Change versus previous monthShort interest in Crescent Biopharma has recently increased by 7.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.45 News SentimentCrescent Biopharma has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Crescent Biopharma this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $285,501.00 in company stock.Percentage Held by Insiders24.84% of the stock of Crescent Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBIO Stock News HeadlinesThe Nascent Crescent Biopharma Thesis: One Year Later And Things Are SteadySeptember 25 at 11:52 PM | seekingalpha.comCrescent Biopharma (NASDAQ:CBIO) & XTL Biopharmaceuticals (NASDAQ:XTLB) Critical AnalysisSeptember 23, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $130,956.27 in StockSeptember 21, 2026 | americanbankingnews.comCrescent Biopharma (NASDAQ:CBIO) COO Sells $64,149.69 in StockSeptember 21, 2026 | americanbankingnews.comBarbara Harlin Bispham Sells 620 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20, 2026 | americanbankingnews.comEllie Eunkyung Im Sells 623 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20, 2026 | americanbankingnews.comInsider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells 568 SharesSeptember 19, 2026 | insidertrades.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $11.86 at the start of the year. Since then, CBIO stock has increased by 18.0% and is now trading at $13.99. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) posted its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.00. When did Crescent Biopharma's stock split? Crescent Biopharma's stock reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Crescent Biopharma IPO? Crescent Biopharma (CBIO) raised $56 million in an initial public offering on Friday, January 10th 2014. The company issued 7,000,000 shares at $8.00 per share. Who are Crescent Biopharma's major shareholders? Crescent Biopharma's top institutional shareholders include Opaleye Management Inc. (3.55%), BlackRock Inc. (4.61%), Bank of New York Mellon Corp (0.17%) and Stonepine Capital Management LLC (0.11%). Insiders that own company stock include Fairmount Funds Management Llc, Joshua T Brumm, Jonathan Mcneill, Jan Pinkas, Ellie Eunkyung Im, Richard William Scalzo, Barbara Harlin Bispham and Ryan Lynch. View institutional ownership trends. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings7/30/2026Today9/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 4 days ago, CBIO's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone(617) 430-5595Fax336-480-2107Employees44Year Founded2003Price Target and Rating Average Price Target for Crescent Biopharma$29.60 High Price Target$35.00 Low Price Target$22.00 Potential Upside/Downside+111.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.94 million Net MarginsN/A Pretax Margin-1,372.75% Return on Equity-101.50% Return on Assets-86.86% Debt Debt-to-Equity RatioN/A Current Ratio9.66 Quick Ratio9.66 Sales & Book Value Annual Sales$10.84 million Price / Sales47.93 Cash FlowN/A Price / Cash FlowN/A Book Value$14.32 per share Price / Book0.98Miscellaneous Outstanding Shares37,140,000Free Float27,917,000Market Cap$519.59 million OptionableNo Data Beta1.24 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CBIO) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CBIO Stock Alerts